The first thing you notice is the stillness. In a video from one of Multiply Labs's facilities, a multi-armed robotic cluster, all white plastic and brushed aluminum, moves through a sequence of fluid transfers with a quiet, unhurried precision. There are no lab-coated technicians rushing between stations, no hands reaching into biosafety cabinets. The robot is performing a cell therapy manufacturing protocol, a series of steps that would normally require a small team of highly trained humans working in a sterile cleanroom. It looks less like a factory and more like a ballet, choreographed in code and executed by machines that never get tired, never sneeze, and never have a bad day. This is the company's core proposition: what if the most delicate, individualized work in medicine could be handed off to a machine that learned by watching?
Multiply Labs, founded in 2016 by MIT alumni Fred Parietti and Alice Melocchi, is building robotic biomanufacturing infrastructure for the pharmaceutical industry. Its systems are modular, cloud-controlled robotic clusters designed to automate the sterile, high-throughput manufacturing steps for precision medicines and, more recently, the booming field of cell and gene therapies. The company started with a focus on personalized polypills, using 3D printing to create custom medication capsules [Forbes, 2019]. That initial wedge into pharmaceutical robotics has since evolved into a broader platform. Today, Multiply Labs sells both the physical robotic systems and a companion software suite called Digital QC, which handles process planning, real-time sensor monitoring, and the creation of comprehensive electronic batch records required by regulators [Multiply Labs].
From personalized pills to industrial-scale cells
The company's pivot mirrors a larger shift in the biotech landscape. The promise of cell therapies,where a patient's own immune cells are extracted, genetically modified to fight cancer, and reinfused,is colliding with a manufacturing bottleneck. These therapies are not pills stamped out by the billion; each dose is a bespoke product, crafted from a single patient's biology. The process is labor-intensive, prone to human error, and extraordinarily expensive. Multiply Labs's bet is that robotics, guided by software that learns from human demonstrations (a technique they call "imitation learning"), can bring the scale, consistency, and cost-effectiveness of industrial automation to this most human-scale of tasks [PERPLEXITY SONAR PRO BRIEF].
Their approach is not to replace every piece of lab equipment but to build the orchestration layer. The robotic clusters are designed to be compatible with market-leading GMP (Good Manufacturing Practice) instruments, acting as the hands that move samples between incubators, centrifuges, and bioreactors [Multiply Labs]. The Digital QC software sits on top, creating a digital thread that tracks every action and measurement, aiming for full CFR Part 11 compliance for electronic records. The vision is a "pharma robotics as a service" model, where Multiply Labs deploys these systems into customer facilities and sells robotic production capacity [Y Combinator].
The traction: blue-chip pharma as proof of concept
For a deep-tech hardware startup, traction is measured in partnerships and pilot deployments, not monthly active users. Multiply Labs has quietly assembled a roster of partners that reads like a who's who of advanced therapy developers.
- AstraZeneca. The pharmaceutical giant is working with Multiply Labs to evaluate multi-arm robotic clusters for commercial-scale production of cell therapies [Contract Pharma].
- Legend Biotech & Kyverna Therapeutics. Both are named customers automating cell therapy manufacturing with Multiply Labs's robots [Multiply Labs]. In 2025, Kyverna entered a specific pilot to use the technology for its next-generation CAR T candidate, KYV-102 [Multiply Labs, 2025].
- Thermo Fisher Scientific. An expanded collaboration aims to integrate Multiply Labs's robotic technology with Thermo Fisher's instruments to achieve end-to-end automation [Business Wire, 2024].
- Stanford University. The company is deploying systems at Stanford's Laboratory for Cell and Gene Medicine (LCGM), a top-tier GMP facility, serving as both a testbed and a showcase [Multiply Labs].
This customer base has attracted significant capital. The company has raised approximately $41.3 million from 24 institutional investors, including a $25 million Series A led by Casdin Capital in 2021 and an $11.1 million follow-on round in 2023 [The Pharma Letter]. The investor list includes Y Combinator, Lux Capital, and Teradyne Ventures, blending biotech and hard-tech expertise. Headcount has grown to approximately 67 employees as of early 2026 [LeadIQ, 2026].
| Role | Name | Background |
|---|---|---|
| CEO & Co-Founder | Fred Parietti, Ph.D. | MIT alum; leads company strategy and vision. |
| CSO & Co-Founder | Alice Melocchi | Associate Professor at Università degli Studi di Milano; provides scientific direction. |
The company is also expanding its physical footprint, establishing a manufacturing subsidiary, Multiply Labs Italia, in Turin to build robotic clusters for its growing European pharmaceutical customer base [Multiply Labs].
Where the wheels could come off
The ambition is vast, and the path is littered with the wreckage of startups that tried to automate complex, regulated processes. The risks for Multiply Labs are not trivial.
- The integration marathon. Selling into Big Pharma is a famously long and complex sales cycle. Pilots can last years before becoming revenue-generating deployments. The capital-intensive nature of building hardware means the company must manage its burn rate carefully against this slow-moving customer adoption curve.
- The black box of biology. Cell therapy manufacturing is not assembling a smartphone. Biological processes are variable; cells behave differently from donor to donor. A robot executing a perfect protocol on a non-viable cell batch still yields a failed product. The company's software must be intelligent enough to handle this variability, which may require moving beyond imitation learning toward more adaptive AI.
- Regulatory acceptance. While the Digital QC software is designed to be compliant, regulators like the FDA will need to sign off on therapies manufactured primarily by robots. Any misstep in data integrity or process validation could set the entire category back.
- Competitive response. While no direct competitors are named in public sources, the opportunity is too large to ignore. Established lab automation giants (like Thermo Fisher, through its own divisions) and new entrants could develop similar systems, turning a first-mover advantage into a costly standards war.
Multiply Labs's answer to these challenges appears to be a focus on deep collaboration rather than displacement. By partnering with instrument makers like Thermo Fisher and premier research institutions like Stanford, they are embedding themselves in the existing ecosystem. Their use of NVIDIA's Isaac and Omniverse platforms for simulation and scaling suggests a commitment to building on robust, industry-accepted tools [NVIDIA Blog]. The bet is that by being the best orchestrator, not the only equipment provider, they can become the default operating system for next-generation biomanufacturing.
The next twelve months
The coming year will be about converting pilots into scaled contracts. The collaborations with AstraZeneca, Kyverna, and Legend Biotech are the leading indicators. A public announcement of a full commercial deployment at any of these partners would be a watershed moment, proving that the robotics-as-a-service model can move beyond the pilot phase. The expansion in Italy will test the company's ability to manufacture its own systems at volume while maintaining the precision required. And on the horizon, the inevitable question of a Series B will loom, as the capital required to outfit global pharmaceutical factories will far exceed the $41 million raised to date.
Ultimately, the question Multiply Labs is trying to answer is not merely technical. It's cultural. For decades, the gold standard in biopharma has been the white-coated scientist, the steady human hand in the laminar flow hood. That image is synonymous with safety and care. Multiply Labs is proposing a new icon: the flawless, tireless robotic arm. Its success hinges on convincing an entire industry,from bench scientists to regulatory bodies to patients,that for medicines built one cell at a time, the most human thing to do might be to let the machines take over.
Sources
- [Forbes, February 2019] 50 Women-Led Startups That Are Crushing Tech | https://www.forbes.com/sites/allysonkapin/2019/02/20/50-women-led-startups-who-are-crushing-tech/
- [Multiply Labs] Corporate website, Leadership, Products, and Newsroom pages | https://www.multiplylabs.com
- [PERPLEXITY SONAR PRO BRIEF] Summary of company positioning and technology | Sourced from web-grounded research
- [Y Combinator] Multiply Labs: Robotic production capacity for the pharma manufacturing industry | https://www.ycombinator.com/companies/multiply-labs
- [Contract Pharma] AstraZeneca partnership announcement | Source from raw research snippets
- [Multiply Labs, 2025] Kyverna Therapeutics partnership press release | https://multiplylabs.com/news/
- [Business Wire, 2024] Thermo Fisher Scientific expanded collaboration announcement | Source from raw research snippets
- [The Pharma Letter] Funding round details and investor information | Source from raw research snippets
- [LeadIQ, 2026] Employee headcount data | Source from raw research snippets
- [NVIDIA Blog] Blog post on using NVIDIA Isaac and Omniverse | https://blogs.nvidia.com/blog/multiply-labs-isaac-omniverse/